ProKidney Corp (NASDAQ: PROK) kicked off on Monday, down -12.93% from the previous trading day, before settling in for the closing price of $2.59. Over the past 52 weeks, PROK has traded in a range of $0.46-$7.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 10.31%. With a float of $97.12 million, this company’s outstanding shares have now reached $129.54 million.
Let’s look at the performance matrix of the company that is accounted for 204 employees. In terms of profitability, gross margin is 100.0%, operating margin of -60453.59%, and the pretax margin is -54267.65%.
ProKidney Corp (PROK) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ProKidney Corp is 27.21%, while institutional ownership is 36.61%. The most recent insider transaction that took place on Jul 08 ’25, was worth 312,510. In this transaction Chief Regulatory Officer of this company sold 103,480 shares at a rate of $3.02, taking the stock ownership to the 0 shares. Before that another transaction happened on Jul 08 ’25, when Company’s Officer proposed sale 103,480 for $0.61, making the entire transaction worth $62,761.
ProKidney Corp (PROK) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.16 earnings per share (EPS), higher than consensus estimate (set at -0.18) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.31% per share during the next fiscal year.
ProKidney Corp (NASDAQ: PROK) Trading Performance Indicators
Take a look at ProKidney Corp’s (PROK) current performance indicators. Last quarter, stock had a quick ratio of 10.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2129.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of ProKidney Corp (PROK)
ProKidney Corp (NASDAQ: PROK) saw its 5-day average volume 2.76 million, a negative change from its year-to-date volume of 5.88 million. As of the previous 9 days, the stock’s Stochastic %D was 9.36%.
During the past 100 days, ProKidney Corp’s (PROK) raw stochastic average was set at 26.91%, which indicates a significant increase from 0.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.38 in the past 14 days, which was higher than the 0.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.02, while its 200-day Moving Average is $1.53. Nevertheless, the first resistance level for the watch stands at $2.49 in the near term. At $2.72, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.84. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $2.02. Assuming the price breaks the second support level, the third support level stands at $1.79.
ProKidney Corp (NASDAQ: PROK) Key Stats
The company with the Market Capitalisation of 660.06 million has total of 292,698K Shares Outstanding. Its annual sales at the moment are 80 K in contrast with the sum of -61,190 K annual income. Company’s last quarter sales were recorded 230 K and last quarter income was -16,730 K.
